Skip to Content
Merck
CN

MABN869

Anti-DARPP-32 Antibody, clone 9B6.1

clone 9B6.1, from mouse

Synonym(s):

Protein phosphatase 1 regulatory subunit 1B, DARPP-32, Dopamine- and cAMP-regulated neuronal phosphoprotein

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Anti-DARPP-32 Antibody, clone 9B6.1, clone 9B6.1, from mouse

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

9B6.1, monoclonal

species reactivity

human, rat

technique(s)

immunohistochemistry: suitable
western blot: suitable

isotype

IgG1κ

NCBI accession no.

NP_001229393

UniProt accession no.

Q9UD71

shipped in

wet ice

target post-translational modification

unmodified

Quality Level

100

Gene Information

human ... PPP1R1B(84152)

Application

Research Sub Category
Signaling Neuroscience
This Anti-DARPP-32 Antibody, clone 9B6.1 is validated for use in Western Blotting, Immunohistochemistry for the detection of DARPP-32.
Western Blotting Analysis: 1.0 µg/mL from a representative lot detected DARPP-32 in 10 µg of rat brain tissue lysate.
Immunohistochemistry Analysis: A 1:1000 dilution from a representative lot detected DARPP-32 in human cerebral cortex and human testis tissue.
Research Category
Neuroscience

Biochem/physiol Actions

Expected to react with both spliced isoforms of human DARPP-32 (UniProt Q9UD71-1 & Q9UD71-2).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Analysis Note

Evaluated by Western Blotting in human brain tissue lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected DARPP-32 in 10 µg of human brain tissue lysate.

General description

Protein phosphatase 1 regulatory subunit 1B (EC 3.1.3.16; UniProt Q9UD71; also known as DARPP-32, Dopamine- and cAMP-regulated neuronal phosphoprotein 32) is encoded by the PPP1R1B (also known as DARPP32) gene (Gene ID 84152) in human. DARPP-32 is a PKA substrate that, upon phosphorylation on Thr34 by PKA, functions as a protein-phosphatase 1 (PP1) inhibitor. DARPP-32 N-terminal a.a. 8-11 (KIQF) is essential for PPI binding. DARPP-32 is an important mediator of dopamine receptor-dependent NMDA receptor activation. Dopamine receptor activation leads to cAMP induction, which activates cellular PKA activity and subsequent DARPP-32 Thr34 phosphorylation. PP1 inhibition by the Thr34 phosphorylated DARPP-32 in turn results in an enhnaced NMDA receptor phosphorylation. Calcium/calmodulin-dependent protein phosphatase 2B (PP2B or calcineurin) can reverse DARPP-32 Thr34 phosphorylation and negatively regulate its PP1 inhibitory activity. DARPP-32 is also known to be phosphorylated on Ser137 by casein kinase I (CKI), on Ser102 by CKII, and on Thr75 by Cdk5. Ser137 phosphorylation prevents PP2B from dephosphorylating pSer34, and Ser102 phosphorylation promotes Thr34 phosphorylation by PKA. Thr75 phosphorylated DARPP-32 is reported to exhibit PKA inhibitory activity in vitro.
~32/30 kDa observed. Target band(s) appears larger than the caluclated molecular weights of 22.96 kDa (isoform 1) and 18.74 kDa (Isoform 2).

Immunogen

Epitope: C-terminal half.
GST-tagged recombinant protein corresponding to the C-terminal half of human DARPP-32.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Preparation Note

Stable for 1 year at 2-8°C from date of receipt.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Neuroscience Solutions for productive research

Alzheimer’s Disease is a progressively deteriorating disease. It manifests itself with memory loss, confusion, problems with judgment, planning, concentration, and personality changes; and in it’s later stages, a decline in physical abilities. The disease’s causes, cures, and preventions are unknown; however, key proteins likely involved in the degenerative mechanism have been identified. Alzheimer’s Disease is characterized by neuronal loss, alterations in neurotransmitter systems, and the presence of neurofibrillary tangles composed of abnormally hyperphosphorylated tau proteins. A prominent feature of Alzheimer’s Disease is the formation of senile plaques in selected regions of the brain. The center of these plaques are composed mainly of fibrillary aggregates of a common, but not well understood, b amyloid peptides (Aβ). The Aβ peptides are generated from the larger amyloid-β precursor protein (APP) by the sequential action of β- and γ-secretase, and it is generally accepted that oligomeric forms of this Aβ are neurotoxic, resulting in disease progression.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service